Gautam Jayram, MD, gives an overview of recently approved agents in NMIBC

In this video, Gautam Jayram, MD, discusses the recently approved agents in non–muscle-invasive bladder cancer (NMIBC). Specifically, he touches on pembrolizumab, approved in 2020, nadofaragene firadenovec-vncg, approved in 2022, and N-803 (Anktiva), approved in 2024. Jayram is a urologic oncologist and director of the Advanced Therapeutics Center at Urology Associates of Nashville in Tennessee.

Video Transcript:

You have nadofaragene [firadenovec], which has been out now for a year or 2. It's intravesical gene therapy with interferon. It's once every 3-month dosing. Now we're starting to get a good balance of data and information about it. A lot of urologists are using it and feel really comfortable with it, and it's really friendly to patients in terms of the dosing schedule. It's easy to give in your practice. That's something that I think has caught on, and people are pretty happy with.

Pembrolizumab was approved a few years ago. We've had some discussions about systemic therapy only in this space and its limitations because of the side effects, and also the data isn't super strong. So, most people are looking more at combination therapy for that, instead of just using pembrolizumab.

And then we have an Anktiva, which was just recently approved. It's an IL-15 agonist that stimulates natural killer cells to really mount an immune response, and I think that that's really exciting. We still are super early in the whole process, so there's a lot of things that need to be figured out, but a lot of groups that are giving some of these other therapies, of course, are going to look at that as well.

There are some differences in terms of how these drugs are handled and stored. The economics of these drugs are a little bit different. So, all of that's going to be an important part of how we pick these therapies and how patients pick these therapies.

This transcript was AI generated and edited by human editors for clarity.